Merrimack Pharmaceuticals (MACK) Receiving Somewhat Favorable News Coverage, Accern Reports
Media stories about Merrimack Pharmaceuticals (NASDAQ:MACK) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 49.0766831377025 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Merrimack Pharmaceuticals (NASDAQ MACK) traded up $0.05 during midday trading on Monday, reaching $10.05. 121,687 shares of the company’s stock traded hands, compared to its average volume of 143,186. The company has a quick ratio of 3.35, a current ratio of 3.35 and a debt-to-equity ratio of 0.45. The firm has a market cap of $133.39, a price-to-earnings ratio of 0.30 and a beta of 1.74. Merrimack Pharmaceuticals has a 52 week low of $9.68 and a 52 week high of $39.90.
About Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.